Cubist's Trius buyout pays off with FDA nod on high-powered antibiotic Sivextro
Less than a year after Cubist ($CBST) scooped up Trius for $707 million in a bid to boost its presence in antibiotics, it can boast an FDA approval out of the deal. On Friday, the agency approved Sivextro, an antibacterial drug to treat a range of skin infections, including methicillin-resistant Staphylococcus aureus (MRSA).
Sivextro (tedizolid phosphate) can be administered orally or intravenously and will be a direct competitor to Pfizer's ($PFE) Zyvox, a widely used antibiotic that brought in $1.4 billion in sales last year. In late-stage trials, Sivextro proved as effective as Zyvox, but with fewer side effects, less frequent dosing, and a shorter treatment time. That could help it compete with upcoming generic versions of Zyvox, which loses its patent protection next year.
Ralph Corey, a professor of medicine and infectious disease at Duke University Medical Center, said in a Cubist press release that when it comes to drug-resistant infections, the more choices the better. "MRSA is still problematic in the U.S. and is responsible for the deaths of more than 11,000 Americans each year," Corey said. "A 6-day course of therapy with the option to choose--and, if needed--change from I.V. to oral administration is a welcome new development."
Cubist made its name in antibiotics on the strength of one product, Cubicin, but the company has been making some major investments in antibiotics R&D. On the same day the company bought Trius, it also picked up Optimer Pharmaceuticals for $535 million. That deal gave Cubist control over Dificid, Optimer's antibiotic to fight Clostridium difficile.
And Cubist has vowed to spend $400 million in R&D this year alone to fund its goal of delivering four new antibiotics by 2020. Sivextro is first in line, followed closely by ceftolozane/tazobactam, an antibiotic to treat complicated urinary tract and intra-abdominal infections; the FDA is expected to decide that drug's fate in late December. Cubist's pipeline includes more drugs to fight C. diff, as well as hospital-acquired bacterial pneumonia candidates.
Cubist's superbug drug clears FDA panel, lines up for Pfizer showdown
Cubist splurges on Trius and Optimer buyouts to spur antibiotics growth
Trius targets key approvals after antibiotic matches Zyvox (again) in Phase III
GSK, Astra among shoppers for $1B Optimer deal: Bloomberg